Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seikagaku Corporation

http://www.seikagaku.co.jp/english/

Latest From Seikagaku Corporation

Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials

VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.

Financing Growth

Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy

Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.

Deal Watch Business Strategies

Delaying Price Increases Dragged Down Colgate’s Q1 Results As Supply Costs Continue Climbing

High costs pummeled Q1 results down 17.9% to $559m. Net sales were up 1.5% to $4.39bn, with price hikes made late in quarter driving a 4% increase in organic sales. Hong Kong firm Hawley & Hazel Co., 50% owned by Colgate since 1985, relaunches Chinese name of its Darlie brand oral care line as Haolai.

Consumer Sales & Earnings

Carogra, Xenpozyme Among Japan World-First Approvals

The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.

Japan Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Seikagaku North America Corporation
UsernamePublicRestriction

Register